Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity

NCT06315972 is registered in ClinicalTrials.gov with LMU Klinikum as lead sponsor.

NCT NCT06315972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06315972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity
Lead sponsor
LMU Klinikum
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2024
Completion date
April 30, 2028
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia